Reset filter
Mots-clés
Afficher plus Mots-clés
Table des matières
  1. 1. Essai clinique
  2. 2. Routinedokumentation
  3. 3. Études de registres/cohortes
  4. 4. Assurance qualité
  5. 5. Standard de données
  6. 6. Questionnaire pour les patients
  7. 7. Spécialité médicale
    1. 7.1. Anesthésie
    1. 7.2. Dermatologie
    1. 7.3. HNO
    1. 7.4. Gériatrie
    1. 7.5. Gynécologie/obstétrique
    1. 7.6. Médecine interne
      1. Hématologie
      1. Infectiologie
      1. Cardiologie/angiologie
      1. Pneumologie
      1. Gastroentérologie
      1. Néphrologie
      1. Endocrinologie/métabolisme
      1. Rhumatologie
    1. 7.7. Neurologie
    1. 7.8. Ophtalmologie
    1. 7.9. Médecine palliative
    1. 7.10. Pathologie/médécine légale
    1. 7.11. Pédiatrie
    1. 7.12. Psychiatrie/psychosomatique
    1. 7.13. Radiologie
    1. 7.14. Chirurgie
      1. Chirurgie générale/viscérale
      1. Neurochirurgie
      1. Chirurgie plastique
      1. Chirurgie cardiaque/thoracique
      1. Chirurgie traumatologique/orthopédie
      1. Chirurgie vasculaire
    1. 7.15. Urologie
    1. 7.16. Médecine dentaire/MKG
Modèles de données sélectionnés

Vous devez être connecté pour sélectionner plusieurs modèles de données, les télécharger ou les analyser.

142 Résultats de recherche.
Pertinence Commentaire Plus récent Moins récent

Eligibility Kidney Cancer NCT00365768

- 03/10/2016 - 1 Formulaire, 2 Groupes Item, 9 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors; ODM derived from: https://clinicaltrials.gov/show/NCT00365768

Eligibility NCT00796757 Renal Cell Cancer - Eligibility

- 09/12/2013 - 1 Formulaire, 2 Groupes Item, 10 Eléments de données, 2 Langues
Groupes Item: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00796757

Treatment Form Kidney Cancer (NCT01198158)

- 08/01/2015 - 1 Formulaire, 6 Groupes Item, 39 Eléments de données, 1 Langue
Groupes Item: Header Module, Patient Information, Urinalysis Day 1, Urinalysis Day 15, Everolimus, Bevacizumab/Placebo Information
CALGB 90802 Treatment Form Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy NCT01198158 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=87963E33-F0BE-4A17-E040-BB89AD433B67

Eligibility Renal Cell Carcinoma NCT00610389

- 20/09/2021 - 1 Formulaire, 2 Groupes Item, 11 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Phase II Study With Immunotherapy With Dendritic Cells and Tumor Infiltrating Lymphocytes in Solid Tumors; ODM derived from: https://clinicaltrials.gov/show/NCT00610389

Eligibility NCT00655252 Metastatic Renal Cell Cancer - Eligibility

- 09/12/2013 - 1 Formulaire, 2 Groupes Item, 10 Eléments de données, 2 Langues
Groupes Item: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00655252

Eligibility Renal Cell Carcinoma NCT00448721

- 28/09/2018 - 1 Formulaire, 2 Groupes Item, 15 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor (TKI) - Failure in Patients With Renal Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00448721

Eligibility Renal Cell Carcinoma NCT00831857

- 29/09/2018 - 1 Formulaire, 1 Groupe Item, 13 Eléments de données, 1 Langue
Groupe Item: Inclusion Criteria
VEGF Imaging in Renal Cell Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT00831857

Eligibility Renal Cell Carcinoma NCT00631371

- 29/09/2018 - 1 Formulaire, 2 Groupes Item, 8 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects; ODM derived from: https://clinicaltrials.gov/show/NCT00631371

Eligibility Renal Cell Carcinoma NCT00417677

- 28/09/2018 - 1 Formulaire, 1 Groupe Item, 19 Eléments de données, 1 Langue
Groupe Item: Criteria
A Study Combining Treatment With Temsirolimus and Sunitinib for Subjects With Advanced Renal Cell Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT00417677

Off-Treatment Form Kidney Cancer (NCT00326898)

- 07/01/2015 - 1 Formulaire, 3 Groupes Item, 24 Eléments de données, 1 Langue
Groupes Item: Header, Vital Status, Treatment
E2805 Off-Treatment Form Sunitinib or Sorafenib in Treating Patients With Kidney Cancer That Was Removed By Surgery NCT00326898 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=054AD4FB-BA76-2822-E044-0003BA3F9857

Eligibility Renal Cell Carcinoma NCT01014065

- 03/09/2018 - 1 Formulaire, 2 Groupes Item, 14 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
A Prospective Study of Acute Cardiovascular Effects of First-line Sunitinib in Metastatic Renal Cell Carcinoma Patients (SUnitinib Prospective CardiovasculaR Effect); ODM derived from: https://clinicaltrials.gov/show/NCT01014065 Sponsor: AHS Cancer Control Alberta Collaborator: Cross Cancer Institute Information provided by (Responsible Party): AHS Cancer Control Alberta Principal Investigator: Mark Haykowsky, PhD University of Alberta

Follow-Up Form Kidney Cancer (NCT01198158)

- 09/01/2015 - 1 Formulaire, 8 Groupes Item, 57 Eléments de données, 1 Langue
Groupes Item: Header Module, Vital Status, Disease Assessment, Measurable Disease Response, LABORATORY DATA, Notice of New Primary, Long-Term Toxicity, Non-Protocol Therapy
CALGB 90802 Follow-Up Form Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy NCT01198158 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=87856A36-E884-CA3E-E040-BB89AD431C27

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial